AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Powered by AMiner. Clicking this button will take you away from SciOpen.
Home Oncology Research Article
PDF (20.9 MB)
Cite
EndNote(RIS) BibTeX
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Case Report | Open Access

Case Report: A Case of Neuroendocrine Carcinoma of the Endometrium with Deficient DNA Mismatch Repair Had Achieved Clinical Complete Response after Combination Therapy

Xie Ding#,1,2,3, Xinfeng Liu#,4, Cheng Dai5, Xiaoxiao Wang1,2,3, Zhaopeng Zheng2,3( )
The Second Clinical College, Zunyi Medical University, Zunyi, China
Department of Oncology, The People’s Hospital of QianNan, Duyun, China
Department of Oncology, Guizhou Provincial People’s Hospital, Guiyang, China
Department of Radiology, Guizhou Provincial People’s Hospital, Guiyang, China
Department of Gynecology, Guizhou Provincial People’s Hospital, Guiyang, China

#These authors contributed equally to this work as the first author

Show Author Information

Abstract

Background

Immunotherapy has markedly reshaped the therapeutic landscape for patients with postoperative progression and metastasis. As a programmed death-1 (PD-1) inhibitor, camrelizumab has been proven to exhibit both efficacy and safety in the treatment of advanced dMMR solid tumors.

Case Description

A 58-year-old female patient with neuroendocrine carcinoma of the endometrium (NECE) who was treated with camrelizumab coupled with chemotherapy, subsequent maintenance monotherapy with camrelizumab, and adjuvant pelvic local radiotherapy. Up to December 2024, the patient has survived 28 months since treatment, with 26 months free from disease progression, and the assessment indicated a status of clinical complete response (cCR).

Conclusion

The combined regimen achieves notable efficacy and is free of unexpected adverse effects, with only a radiotherapy-related pelvic insufficiency fracture (PIF) report.

Keywords

Neuroendocrine carcinoma of the endometrium (NECE)DNA mismatch repair deficiency (dMMR)programmed death-1 (PD-1) inhibitorcamrelizumabcombination chemotherapyadjuvant radiotherapycase report

References

【1】
【1】
 
 
Crossref Google Scholar
Oncology Research
Volume 34 Issue 5,
April 2026
Article number: 37
DOI: 10.32604/or.2026.071213

{{item.num}}

Comments on this article

Go to comment

< Back to all reports

Review Status: {{reviewData.commendedNum}} Commended , {{reviewData.revisionRequiredNum}} Revision Required , {{reviewData.notCommendedNum}} Not Commended Under Peer Review

Review Comment

Cite this Report
Close
Close
Cite this article:
Ding X, Liu X, Dai C, et al. Case Report: A Case of Neuroendocrine Carcinoma of the Endometrium with Deficient DNA Mismatch Repair Had Achieved Clinical Complete Response after Combination Therapy. Oncology Research, 2026, 34(5): 37. https://doi.org/10.32604/or.2026.071213

14

Views

0

Downloads

0

Crossref

0

Web of Science

0

Scopus
Received: 02 August 2025
Accepted: 03 February 2026
Published: 22 April 2026
© The Author 2026.

This work is licensed under a Creative Commons Attribution 4.0 International License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.